Analysis of ARHGAP4 Expression With Colorectal Cancer Clinical Characteristics and Prognosis

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Jul 18

PMID 35847897

Authors

Ming-Sheng Fu

Shu-Xian Pan

Xun-Quan Cai

Yuan-Xin Hu

Wei-Jie Zhang

Qin-Cong Pan

Affiliations

Soon will be listed here.

Abstract

Background: This study aims to analyze the correlation between ARHGAP4 in the expression and clinical characteristics of colorectal cancer (CRC), and the influence of ARHGAP4 expression on the prognosis of CRC, and to evaluate whether ARHGAP4 is a potential prognostic oncotarget for CRC.

Methods: ARHGAP4 was identified using the Gene Expression Omnibus database through weighted gene coexpression network analysis. Using the Gene Expression Profiling Interactive Analysis to perform and analyze the expression and prognosis of ARHGAP4 in CRC. The expression of AGRGAP4 and immune cells was analyzed by the Tumor IMmune Estimation Resource online database. Finally, immunohistochemistry was used to analyze the expression difference and prognosis of ARHGAP4 in CRC and adjacent normal tissues, as well as the relationship between AGRGAP4 expression and clinical features of CRC.

Results: We identified ARHGAP4 that is related to the recurrence of CRC from GSE97781 data. ARHGAP4 has not been reported in CRC. The high expression of ARHGAP4 in select colon adenocarcinoma indicates a poor prognosis by database analysis. In our clinical data results, ARHGAP4 is highly expressed in CRC and lowly expressed in normal tissues adjacent to cancer. Compared with the low-expression group, the high-expression group has a significantly poorer prognosis. In colon cancer, the B-cell, macrophage, neutrophil, and dendritic-cell levels are downregulated after ARHGAP4 gene knockout; the levels of CD8 and CD4 T cells, neutrophils, and dendritic cells are upregulated after the amplification of the ARHGAP4 gene. In addition, ARHGAP4 expression is related to N,M staging and clinical staging.

Conclusion: ARHGAP4 is highly expressed in CRC, and the high expression of ARHGAP4 has a poor prognosis. The expression of ARHGAP4 in CRC is related to the immune cells such as B cells, CD8 and CD4 T cells, macrophages, neutrophils, and dendritic cells. ARHGAP4 is correlated with N,M staging and clinical staging in CRC. ARHGAP4 may be a potential biomarker for the prognosis of CRC.

Citing Articles

A gene signature related to programmed cell death to predict immunotherapy response and prognosis in colon adenocarcinoma.

Zheng L, Lu J, Kong D, Zhan Y PeerJ. 2025; 13:e18895.

PMID: 39950044 PMC: 11823652. DOI: 10.7717/peerj.18895.

Exploration of the ubiquitination-related molecular classification and signature to predict the survival and immune microenvironment in colon cancer.

Xu J, Wan T, Su J, Song J Front Genet. 2024; 15:1292249.

PMID: 39268080 PMC: 11390591. DOI: 10.3389/fgene.2024.1292249.

Inhibits Proliferation and Growth of SW620 Colon Cancer Cells by Cell Cycle and Differentiation Pathways.

Fu M, Pan S, Cai X, Lv C, Pan Q Scientifica (Cairo). 2024; 2024:5791613.

PMID: 38938545 PMC: 11208814. DOI: 10.1155/2024/5791613.

Rho GTPase-activating protein 4 is upregulated in Kidney Renal Clear Cell Carcinoma and associated with poor prognosis and immune infiltration.

Xiao X, Lv X, Lin T, Li J, Wang R, Tian S Cancer Biomark. 2024; 40(2):205-223.

PMID: 38905034 PMC: 11307029. DOI: 10.3233/CBM-230388.

Cai's prescription inhibits granulosa cell apoptosis through ARHGAP4 on poor ovarian responders.

Wang Z, Liu D, Nie Y, Zhang Q J Ovarian Res. 2024; 17(1):40.

PMID: 38355537 PMC: 10865665. DOI: 10.1186/s13048-024-01363-x.

References

Ming-Sheng F, Mei-Ling D, Xun-Quan C, Yuan-Xin H, Wei-Jie Z, Qin-Cong P . Preoperative Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and CEA as the Potential Prognostic Biomarkers for Colorectal Cancer. Can J Gastroenterol Hepatol. 2022; 2022:3109165. PMC: 8752269. DOI: 10.1155/2022/3109165. View

Wang J, Tian X, Han R, Zhang X, Wang X, Shen H . Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer. Oncogene. 2013; 33(9):1181-9. PMC: 3883922. DOI: 10.1038/onc.2013.42. View

Shen Y, Xu L, Ning Z, Liu L, Lin J, Chen H . ARHGAP4 regulates the cell migration and invasion of pancreatic cancer by the HDAC2/β-catenin signaling pathway. Carcinogenesis. 2019; 40(11):1405-1414. DOI: 10.1093/carcin/bgz067. View

Choi S, Kim H, Leng L, Kang I, Jorgensen W, Cho C . Role of macrophage migration inhibitory factor in the regulatory T cell response of tumor-bearing mice. J Immunol. 2012; 189(8):3905-13. PMC: 3466372. DOI: 10.4049/jimmunol.1102152. View

Vogt D, Gray C, Young 3rd W, Orellana S, Malouf A . ARHGAP4 is a novel RhoGAP that mediates inhibition of cell motility and axon outgrowth. Mol Cell Neurosci. 2007; 36(3):332-42. PMC: 2111057. DOI: 10.1016/j.mcn.2007.07.004. View

Chi Z, Li Z, Cheng L, Wang C . Comparison of long-term outcomes after laparoscopic-assisted and open colectomy for splenic flexure cancer. J BUON. 2018; 23(2):322-328. View

Procaccio L, Schirripa M, Fassan M, Vecchione L, Bergamo F, Prete A . Immunotherapy in Gastrointestinal Cancers. Biomed Res Int. 2017; 2017:4346576. PMC: 5512095. DOI: 10.1155/2017/4346576. View

Smith T, Tse M, Read E, Liu W . Regulation of macrophage polarization and plasticity by complex activation signals. Integr Biol (Camb). 2016; 8(9):946-55. PMC: 5148158. DOI: 10.1039/c6ib00105j. View

Okugawa Y, Toiyama Y, Inoue Y, Iwata T, Fujikawa H, Saigusa S . Clinical significance of serum soluble E-cadherin in colorectal carcinoma. J Surg Res. 2012; 175(2):e67-73. DOI: 10.1016/j.jss.2011.11.009. View

10.

Insinna C, Lu Q, Teixeira I, Harned A, Semler E, Stauffer J . Investigation of F-BAR domain PACSIN proteins uncovers membrane tubulation function in cilia assembly and transport. Nat Commun. 2019; 10(1):428. PMC: 6347608. DOI: 10.1038/s41467-018-08192-9. View

11.

Shen Y, Chen G, Zhuang L, Xu L, Lin J, Liu L . ARHGAP4 mediates the Warburg effect in pancreatic cancer through the mTOR and HIF-1α signaling pathways. Onco Targets Ther. 2019; 12:5003-5012. PMC: 6611502. DOI: 10.2147/OTT.S207560. View

12.

Tao L, Zhu Y, Gu Y, Zheng J, Yang J . ARHGAP25: A negative regulator of colorectal cancer (CRC) metastasis via the Wnt/β-catenin pathway. Eur J Pharmacol. 2019; 858:172476. DOI: 10.1016/j.ejphar.2019.172476. View

13.

Bernhagen J, Krohn R, Lue H, Gregory J, Zernecke A, Koenen R . MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med. 2007; 13(5):587-96. DOI: 10.1038/nm1567. View

14.

Grizzi F, Basso G, Borroni E, Cavalleri T, Bianchi P, Stifter S . Evolving notions on immune response in colorectal cancer and their implications for biomarker development. Inflamm Res. 2018; 67(5):375-389. DOI: 10.1007/s00011-017-1128-1. View

15.

Poornakala S, Prema N . A study of morphological prognostic factors in colorectal cancer and survival analysis. Indian J Pathol Microbiol. 2019; 62(1):36-42. DOI: 10.4103/IJPM.IJPM_91_18. View

16.

Berndt S, Gurevich V, Iverson T . Crystal structure of the SH3 domain of human Lyn non-receptor tyrosine kinase. PLoS One. 2019; 14(4):e0215140. PMC: 6457566. DOI: 10.1371/journal.pone.0215140. View

17.

Fridman W, Zitvogel L, Sautes-Fridman C, Kroemer G . The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017; 14(12):717-734. DOI: 10.1038/nrclinonc.2017.101. View

18.

Kang N, Matsui T, Liu S, Fujiwara S, Deguchi S . Comprehensive analysis on the whole Rho-GAP family reveals that ARHGAP4 suppresses EMT in epithelial cells under negative regulation by Septin9. FASEB J. 2020; 34(6):8326-8340. DOI: 10.1096/fj.201902750RR. View

19.

Lue H, Thiele M, Franz J, Dahl E, Speckgens S, Leng L . Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene. 2007; 26(35):5046-59. DOI: 10.1038/sj.onc.1210318. View

20.

Canel M, Serrels A, Frame M, Brunton V . E-cadherin-integrin crosstalk in cancer invasion and metastasis. J Cell Sci. 2013; 126(Pt 2):393-401. DOI: 10.1242/jcs.100115. View